Author:
Cohen Roger B.,Aamdal Steinar,Nyakas Marta,Cavallin Maria,Green Darron,Learoyd Maria,Smith Ian,Kurzrock Razelle
Reference11 articles.
1. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers;Adjei;J Clin Oncol,2008
2. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial;Falchook;Lancet Oncol,2012
3. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial;Infante;Lancet Oncol,2012
4. Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC);Janne;J Clin Oncol,2012
5. Phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumours;Leijen;Clin Cancer Res,2012
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献